Search

Dear Colleagues, In the past decade there have been many exciting advancements in refractive cataract surgery. With the latest intraocular lens technology and a variety of lens options available, clinicians can customize treatment and maximize outcomes for each and every patient. In this issue of...

When evaluating the patient, it is important to get to know them well. What do they do for a living? Are they retired? What are their visual demands in life? Do they do a lot of nighttime driving or spend a lot of time on the computer? What are their visual priorities? One critical question to ask...

Careful assessment and management of the ocular surface is vital for optimal post operative refractive outcomes. The air-tear film interface is the highest index of refraction and can interfere with preoperative measurements if it is unstable or there is underlying corneal pathology as listed below...

Dear Colleagues, In this issue of eye Insights, we take a close look at posterior uveitis. Inside, you’ll find techniques and tips for evaluating and managing patients with this condition. Due to its many etiologies, posterior uveitis can be challenging to treat until the cause of the inflammation...

The most common symptoms of posterior uveitis are blurred vision and floaters, and the most common signs are chorioretinal infiltrates and vitreous cells. Posterior uveitis is diagnosed by slit lamp examination and indirect ophthalmoscopy. Imaging modalities, including fundus autofluorescence...

While gene therapy is not yet widely available for inherited retinal disorsers (IRDs), researchers are making exciting discoveries, and the future looks more promising than ever before. In this issue of eye Insights, we provide a look into current offerings in gene therapy, and a glimpse into the...

Inherited retinal disorders are rare, hereditary disorders caused by mutations in genes that encode proteins needed for normal retinal health and function. The first gene associated with retinitis pigmentosa was identified at Mass Eye and Ear in 1990, and since then, over 250 IRD-causing genes have...

The first gene-augmentation therapy for an IRD was approved by the U.S. Food and Drug Administration (FDA) in December 2017 after nearly two decades of development in preclinical models and clinical trials. The drug, known as Luxturna®, is for individuals with autosomal recessive retinal dystrophies...

Harvard Ophthalmology research contributions have resulted in major advancements in medical science and ophthalmic practice. Discoveries made in various fields—including genetics, immunology and ocular biology—have reshaped the foundations of ophthalmology and formed many new paradigms for the...